NoneChiefs edge Panthers, Lions rip Colts as Dallas stuns Washington

SEC fines Oklahoma, Auburn after fans storm field in upsets over Alabama, Texas A&MIn a launch weekend already packed with Path of Exile 2 and Marvel Rivals players, Infinity Nikki has also claimed 10 million downloads

Lara Williams: Why are my vegan friends going back to meat?Riding the subway is a rite of passage for those living in and visiting New York City. Surely, if you spent 16 seasons playing football in the Big Apple, you would have hopped on the train at least a handful of times. Not Eli Manning. The former Giants quarterback shared a photo of himself on X at an underground station this week with the caption, “First time riding the subway!” Fans and New Yorkers alike were, understandably, blown away. “Dude has lived in NYC area for 20 years and it’s the first time ever riding on the subway? Thats absurd,” Jake Asman wrote on the platform. “Best evidence the Giants are a New Jersey team,” Politico’s Jeff Coltin joked. “Congestion pricing is working. This middle aged man from New Jersey is riding public transit,” an X user named Matt Janiga wrote. “I forgot how rich people have it sometimes,” @JetsMuse wrote . The social media version of Manning can be a bit of a troll, as he proved this week with a back-and-forth with Tom Brady , so it’s unclear if it was truly the two-time Super Bowl champion’s first time on the subway. On Monday, Brady shared a photo holding a fish while basking in the sunlight — Manning seized on the opportunity, sharing a side-by-side shot of his much larger catch in comparison on Instagram with the caption, “Cute Minnow, Tom!” “You use a helmet to catch that one too?” Brady quipped, in a callback to the Patriots-Giants Super Bowl clash at the end of the 2007 season.

Trump has flip-flopped on abortion policy. His appointees may offer clues to what happens next"Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum." Section 1.10.32 of "de Finibus Bonorum et Malorum", written by Cicero in 45 BC "Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem. Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?" 1914 translation by H. Rackham "But I must explain to you how all this mistaken idea of denouncing pleasure and praising pain was born and I will give you a complete account of the system, and expound the actual teachings of the great explorer of the truth, the master-builder of human happiness. No one rejects, dislikes, or avoids pleasure itself, because it is pleasure, but because those who do not know how to pursue pleasure rationally encounter consequences that are extremely painful. Nor again is there anyone who loves or pursues or desires to obtain pain of itself, because it is pain, but because occasionally circumstances occur in which toil and pain can procure him some great pleasure. To take a trivial example, which of us ever undertakes laborious physical exercise, except to obtain some advantage from it? But who has any right to find fault with a man who chooses to enjoy a pleasure that has no annoying consequences, or one who avoids a pain that produces no resultant pleasure?" 1914 translation by H. Rackham "But I must explain to you how all this mistaken idea of denouncing pleasure and praising pain was born and I will give you a complete account of the system, and expound the actual teachings of the great explorer of the truth, the master-builder of human happiness. No one rejects, dislikes, or avoids pleasure itself, because it is pleasure, but because those who do not know how to pursue pleasure rationally encounter consequences that are extremely painful. Nor again is there anyone who loves or pursues or desires to obtain pain of itself, because it is pain, but because occasionally circumstances occur in which toil and pain can procure him some great pleasure. To take a trivial example, which of us ever undertakes laborious physical exercise, except to obtain some advantage from it? But who has any right to find fault with a man who chooses to enjoy a pleasure that has no annoying consequences, or one who avoids a pain that produces no resultant pleasure?" To keep reading, please log in to your account, create a free account, or simply fill out the form below.PREP ROUNDUP: Cass wrestlers go 8-1 at TRC Super DualsPolice release new photos as they search for the gunman who killed UnitedHealthcare CEO

Seaspan Corporation Signs Agreement with KVH to Equip Fleet with OneWeb Low Earth Orbit SolutionChiefs edge Panthers, Lions rip Colts as Dallas stuns Washington

Minister Harjit Sajjan skipped the Taylor Swift concert following the fracas over free ticketsTammy Hembrow And Matthew Zukowski Officially Tie The Knot Following Months Of Breakup RumoursJACKSON, Miss. (AP) — Clarke Reed , a Mississippi businessman who developed the Republican Party in his home state and across the South starting in the 1960s, died Sunday at his home in Greenville, Mississippi. He was 96. Reed was chairman of the Mississippi Republican Party from 1966 to 1976, beginning at a time when Democrats still dominated in the region. During the 1976 Republican National Convention, delegates were closely divided between President Gerald Ford and former California Gov. Ronald Reagan. Reed united the Mississippi delegation behind Ford — a move that created a decadeslong feud with William D. “Billy” Mounger, another wealthy businessman who was prominent in the Mississippi Republican Party. Reed recalled in a 2016 interview with The Associated Press that delegates faced considerable pressure. Movie stars visited Mississippi's 30 delegates to push for Reagan, and Betty Ford called on behalf of her husband. Reagan met twice with the Mississippi delegation — once with his proposed running mate, Pennsylvania Sen. Richard Schweiker — and once without, according Haley Barbour, who was executive director of the Mississippi Republican Party in 1976 and served as the state's governor from 2004 to 2012. “Everybody was coming to see us," Reed said. “These poor people had never seen this before, the average delegate.” Mississippi delegates were showing the stress at a meeting away from the convention floor in Kansas City, Reed said. “I looked out, and about half of them were crying," he said. Reed initially supported Reagan, but said he moved into the Ford camp because he thought Reagan made “a hell of a mistake” by choosing a more liberal northeastern running mate in a gambit to win support of the unpledged Pennsylvania delegation. “In my opinion, Reagan was the best president of my lifetime. I didn’t know that then,” Reed said in 2016. “And had he been elected with Schweiker, he might’ve gotten a bullet one inch over and Schweiker would’ve been president.” Ford won the party nomination during the convention, then lost the general election to Jimmy Carter, the Democratic former governor of Georgia. Reed was born in Alliance, Ohio, in 1928, and his family moved to Caruthersville, Missouri, when he was about six months old. He earned a business degree from the University of Missouri in 1950. He and Barthell Joseph, a friend he had met at a high school boarding school, founded an agriculture equipment business called Reed-Joseph International, which used technology to scare birds away from farms and airports. Republican U.S. Sen. Roger Wicker of Mississippi said Monday that Reed was “a mentor, supporter and advisor to me for over 56 years." Wicker said he was 21 when Reed put him on the Republican Platform Committee in 1972. “There is no more significant figure in the development of the modern day Mississippi Republican Party than Clarke Reed,” Wicker wrote on social media. “Our state has lost a giant."

Abortion law experts said Trump’s decision to include fewer candidates with deep ties to the anti-abortion movement could indicate that abortion will not be a priority for Trump’s administration.

After three losses this year by a combined eight points, Northwestern has found the finishing touch, winning three straight games, all against power conference teams. Northwestern (9-3) tries to extend its streak Sunday in Evanston, Ill., when it takes on Northeastern (8-4) in the final nonconference game for each team. Making a difference recently for the Wildcats has been their defensive pressure and care of the ball. During the Wildcats' three-game run, which included a 70-66 win in overtime against then-No. 19 Illinois, they forced 45 turnovers while committing just 18. That translates to a 43-16 edge in points off the mistakes. "That's something we've really talked about as a team," Northwestern coach Chris Collins said after an 84-64 win over DePaul on Dec. 21. "We're a really good defensive team and we need to turn some of those live-ball turnovers, so points can come a little easier." Brooks Barnhizer has done a little bit of everything during the Wildcats' mini-streak, averaging 19.3 points, 10.7 rebounds, 3.3 steals, 3.3 assists and 2.7 blocks. Nick Martinelli has continued to excel with his rare skill set, combining crafty work in the paint with his expanded range from the perimeter. The left-hander has averaged 22 points in the last three games. For the year, Martinelli has hit 14 of 25 shots (56 percent) from beyond the arc. For Northeastern of the Coastal Athletic Association, this is the only game on its schedule against a power conference team. In 19 seasons under coach Bill Coen, Northeastern has pulled off nine victories over major conference foes. With an all-junior starting lineup, the Huskies are off to their best start since the 2015-16 season. Northeastern is led by guards Rashad King, who averages 17.7 points, 7.1 rebounds and 4.0 assists per game, and Harold Woods, who puts up 14.2 points, 8.3 rebounds and 2.7 assists. Considering both are perimeter players, the rebounding numbers are extraordinary, especially for the 6-foot-5 Woods. "He hunts for those offensive rebounds and the tight spaces where he can finish behind the defense," Coen said. "And he works on that daily." This is the first meeting of the teams since 1993. The Wildcats hold a 3-1 edge in the series. --Field Level Media

WARREN, N.J., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") TVGN , a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today expresses gratitude to shareholders for their unwavering support and trust in Tevogen Bio and its leadership. The commitment fuels the company's determination to advance its mission of developing accessible, life-saving therapeutics. The company recently announced significant progress through its third quarter financial results for 2024, including, reduction of a net loss by $52.5 million, elimination of nearly all liabilities, and reiterating availability of sufficient capital to fund operations for the next 33 months. Ryan Saadi, MD, MPH, Founder and CEO, Tevogen Bio commented, "We remain steadfast in our mission to advance medical science, however as CEO of the company, preservation of shareholder value remains a priority. We urge all stakeholders to consider the profound impact short selling innovative healthcare companies has on lifesaving therapies. While stock price fluctuations are part of the public market dynamics, Tevogen Bio is acutely aware of the undue influence short sellers have." William Keane, VP of Strategic Initiatives, and graduate of the FBI National Academy stated, "We are aware and monitoring the actions of potential short selling activity targeting our company. We will continue to bring light to this situation and will work with the appropriate authorities as needed." The company plans to provide further updates on its progress in the coming weeks. About Tevogen Bio Tevogen is a clinical-stage specialty immunotherapy company harnessing one of nature's most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence. Tevogen is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen's leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation. Forward-Looking Statements This press release contains certain forward-looking statements, including without limitation statements relating to: expectations regarding the healthcare and biopharmaceutical industries; Tevogen's development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases, cancer and neurological disorders, including TVGN 489 for the treatment of COVID-19 and Long COVID; Tevogen's ability to develop additional product candidates, including through use of Tevogen's ExacTcell platform; the anticipated benefits of ExacTcell; expectations regarding Tevogen's future clinical trials; and Tevogen's ability to generate revenue in the future. Forward-looking statements can sometimes be identified by words such as "may," "could," "would," "expect," "anticipate," "possible," "potential," "goal," "opportunity," "project," "believe," "future," and similar words and expressions or their opposites. These statements are based on management's expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company's control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements. Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the effect of the recent business combination with Semper Paratus Acquisition Corporation (the "Business Combination") on Tevogen's business relationships, operating results, and business generally; the outcome of any legal proceedings that may be instituted against Tevogen; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; costs related to the Business Combination and the failure to realize anticipated benefits of the Business Combination; the failure to achieve Tevogen's commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; the ability to develop, license or acquire new therapeutics; that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk of regulatory lawsuits or proceedings relating to Tevogen's business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen's limited operating history; and those factors discussed or incorporated by reference in Tevogen's Annual Report on Form 10-K and subsequent filings with the SEC. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law. Contacts Tevogen Bio Communications T: 1 877 TEVOGEN, Ext 701 Communications@Tevogen.com © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Chiefs edge Panthers, Lions rip Colts as Dallas stuns WashingtonNone

Tottenham suffered a crushing defeat against their bitter London rivals in Sunday’s dramatic clash, failed to hold a 2-0 lead to eventually lose 4-3. The Lilywhites were the architects of their own downfall, conceding two penalties in the second half that swung the momentum in Chelsea’s favour. With the score at 3-2 in the 83rd minute, Spurs still had a chance to salvage a result. However, a reckless challenge on Cole Palmer inside the box dashed their hopes. The performances of Pape Matar Sarr and Yves Bissouma came under heavy scrutiny , as both midfielders struggled throughout, with Bissouma’s wild tackle on Moises Caicedo adding to Tottenham’s costly mistakes. It would have been a draw if not for Sarr’s horrendous tackle Chelsea was a story of missed chances and costly errors. Jadon Sancho had the chance to play a simple pass but hesitated, giving Cole Palmer time to shift away from goal. What followed was a reckless challenge from Pape Matar Sarr, gifting Chelsea a penalty that Palmer ice cold converted with a cheeky Panenka. Veteran turned pundit, Troy Deeney criticised Sarr for the reckless challenge that led to Chelsea’s fourth goal, noting that not a single Spurs player protested the decision. Deeney highlighted how, with the score at 3-2, Tottenham were still in the game as Chelsea faced a dilemma of whether to attack or maintain possession. However, Palmer moved away from goal, only for the Spurs midfielder to commit a rash challenge that left no room for complaints from his teammates. Speaking to match of the day 2 , Troy Deeney explained “This point (for the fourth goal). It’s 3-2. You’re still in the game,” “Chelsea are now between do we go for it or do we keep the ball. Palmer got away from goal. But look at that, that’s reckless. No one even complains.” Excluding a few names from the teamsheet, every player had a poor performance in the game against Chelsea, highlighting the urgent need for improvement across the squad. The ongoing injury crisis is actively increasing the team’s struggles, and with the pressure mounting, Ange Postecoglou will need to work wonders if he is to save his job. This article first appeared on To The Lane And Back and was syndicated with permission.

Doctor at the heart of Turkey's newborn baby deaths case says he was a 'trusted' physicianChiefs edge Panthers, Lions rip Colts as Dallas stuns WashingtonATLANTA (AP) — Ahmad Robinson scored 21 points as Mercer beat Georgia State 71-68 on Saturday. Robinson had nine rebounds, 10 assists, and three steals for the Bears (7-6). Tyler Johnson went 7 of 15 from the field (3 for 10 from 3-point range) to add 19 points. Cam Bryant shot 4 for 7, including 3 for 6 from beyond the arc to finish with 11 points. The Bears outscored the Panthers 10-4 over the final 4 1/2 minutes. The Panthers (4-9) were led in scoring by Cesare Edwards, who finished with 20 points and two steals. Georgia State also got 14 points from Malachi Brown. Zarigue Nutter also put up 14 points and four assists. The Panthers prolonged their losing streak to six straight. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .

Firefighters and passengers hurt after train hits fire truck on crossing'Let's not panic': Canada picks up the pieces after ugly Latvia loss at world juniors

Nasdaq CFO Sarah Youngwood to Present at the Goldman Sachs U.S. Financial Services ConferenceMagnifica Unveils the Future of Luxury Living at December 9th Launch Event Orlando, FL - December 2024